Skip to content

Hypoalbuminemia in Burn Patients

Hypoalbuminemia in Burn Patients: Should we Care? - A Randomized Controlled Clinical Pilot Trial

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01436292
Acronym
Halburns
Enrollment
0
Registered
2011-09-19
Start date
2011-09-30
Completion date
2015-10-31
Last updated
2022-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second or Third Degree Burns

Keywords

Hypoalbuminemia, Burns, Albumin, Organ dysfunction, Outcome

Brief summary

The purpose of this study is to determine whether 5% human albumin solution, given to correct hypoalbuminemia, could improve organ dysfunction in burn patients as assessed by a change in the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or died).

Detailed description

Each year approximately 2 million people are burned in the USA, from which 80,000 are hospitalized and 6,500 die. It is a well known fact that the two most important factors for mortality in burn patients are age and percent total body surface area burn (TBSA), which are unmodifiable findings. A predictable inflammatory response takes place after a burn injury leading to profound changes in patient homeostasis. As a result, hypoalbuminemia is one of the common finding in severe burn patients. 21% of hospitalized adult patients are hypoalbuminemic on admission. After admission, worsening of existing hypoalbuminemia and development of de novo one are frequently seen. Moreover, hypoalbuminemia, a potentially modifiable variable, has been strongly associated with poor clinical outcomes in critically ill patients and in burn patients. Dynamic organ dysfunction scores have been introduced in critically ill patients few years ago in order to describe the evolution of patients on a daily basis. The Sequential Organ Failure Assessment (SOFA) score is now one of the most accepted score in critically ill patients and has been validated in general medico-surgical unit, as well as in trauma and cardiac surgery patients. It encompasses components assessing six organ functions. This score has also been shown to predict mortality in critically ill patients and in burn patients when used in a dynamic way.

Interventions

DRUG5% human albumin solution (HAS)

Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level: ≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS.

Sponsors

Centre de Recherche du Centre Hospitalier de l'Université de Montréal
CollaboratorOTHER
Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients admitted to the BICU in the Centre hospitalier de l'Université de Montréal within 24 hours following their thermal burn injury. 2. Patients with second or third degree burns greater or equal than 20% of total body surface area. 3. Patients aged 18 years or older. -

Exclusion criteria

1. Patients with serum albumin greater than 30 g/dl at the time of randomization. 2. Patients with a do not resuscitate order. 3. Patients needing total parenteral nutrition. 4. Patients with the following chronic diseases that could affect baseline SOFA calculation or serum albumin levels: end-stage kidney disease, nephrotic syndrome, hepatitis, exudative enteropaty, chronic thrombocytopenia or hematological malignancy. 5. Patients with a known reaction to albumin. 6. Pregnant or lactating women. 7. Patients younger than 18 years old. -

Design outcomes

Primary

MeasureTime frame
Organ dysfunction as assessed by a change in the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or died).Seven days

Secondary

MeasureTime frame
ICU and hospital length of stay1, 3 and 6 months
Free days of mechanical ventilationSeven days
Caloric intakeSeven days
ICU and hospital mortality1, 3 and 6 months
Incidence of infectionSeven days
Time to complete coverage defined as the time between admission and last surgery for grafting1, 3 and 6 months
Fluid balanceSeven days

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026